Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572572 · ClinicalTrials.gov registry record · Phase 3
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
A Phase 3 study of Germ Cell Tumors, sponsored by Hoosier Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 69
- Enrollment target
- 6
- Study locations
NCT00572572 is a Phase 3 study of Germ Cell Tumors that has completed, run by Hoosier Cancer Research Network. The registered enrollment target is 69 participants, roughly in line with the 71-participant average among 3 other Germ Cell Tumors trials with a reported enrollment target. The trial reports 6 study locations across 5 states.
The verdict
NCT00572572, a Phase 3 study of Germ Cell Tumors, has completed, sponsored by Hoosier Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 69 participants
- Enrollment target
- 6
- Study locations
Study Summary
Aprepitant is currently approved for prophylaxis of acute and delayed CINV for highly emetogenic chemotherapy regimens, including cisplatin; however, it has not yet been studied in multiple-day chemotherapy treatment programs. This study will compare the addition of aprepitant compared to placebo administered on days 3,4,5 of chemotherapy administration for acute CINV prophylaxis with standard antiemetic prophylaxis and days 6 and 7 for delayed CINV prophylaxis in a double-blind, randomized, crossover study design.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aprepitant
Study Locations (6)
Indiana
- Indiana University Simon Cancer Center - Indianapolis
- Medical Consultants, P.C. - Muncie
Missouri
- Siteman Cancer Center - St Louis
Oregon
- Providence Portland Medical Center - Portland
Pennsylvania
- University of Pennsylvania - Philadelphia
Wisconsin
- Froedtert/Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00572572
The ClinicalTrials.gov registry entry for NCT00572572 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 71-participant average among 3 other Germ Cell Tumors trials with a reported enrollment target. The listed sponsor is Hoosier Cancer Research Network, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Germ Cell Tumors appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00572572 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Indiana, Missouri, Oregon.
Frequently Asked Questions
What is clinical trial NCT00572572 about?
NCT00572572 is a clinical study titled "Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors". Aprepitant is currently approved for prophylaxis of acute and delayed CINV for highly emetogenic chemotherapy regimens, including cisplatin; however, it has not yet been studied in multiple-day chemotherapy treatment programs. This study will compare the addition of aprepitant compared to placebo ad...
What is the current status of trial NCT00572572?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 69 participants. The study started on 2007-12. Estimated completion is 2011-02.
What conditions does trial NCT00572572 study?
This clinical trial studies the following conditions: Germ Cell Tumors.
What interventions are being tested in trial NCT00572572?
The interventions under investigation include: Placebo (DRUG), Aprepitant (DRUG).
Who is sponsoring clinical trial NCT00572572?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00572572 being conducted?
This trial has 6 study locations across Indiana, Missouri, Oregon, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RECRUITING · Phase 1
-
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.